Revolution Medicines started shipping daraxonrasib to physicians and patients under an FDA-authorized early access program for pancreatic cancer. CEO Mark Goldsmith told STAT the company is now distributing the experimental therapy while it awaits approval. The company positioned the move as a response to strong patient demand following Phase 3 results it said showed patients receiving daraxonrasib lived nearly twice as long as those on standard chemotherapy—an outcome Revolution said is unprecedented in the pancreatic cancer field. Early access shipping can accelerate real-world data collection and clinical uptake, while also putting regulatory momentum under the microscope as the FDA decision process continues.